Landsteiner-Alter Award and Lectureship

This award was initiated in 1954 as the Karl Landsteiner Memorial Award and Lectureship, honoring Karl Landsteiner, MD, whose lifetime research laid the foundation for modern blood transfusion therapy. Landsteiner was awarded the 1930 Nobel Prize in Physiology or Medicine for his research. The award was renamed the Landsteiner-Alter Award in 2021 to also honor Harvey Alter, MD, longtime AABB member and leader in transfusion medicine, who received the 2020 Nobel Prize in Physiology or Medicine for his research leading to the identification of the Hepatitis C virus. The Landsteiner-Alter Award recognizes a scientist whose original research has resulted in an important contribution to the body of scientific knowledge. The scientist who receives the award should have an international reputation in transfusion medicine or biotherapies.

Eligibility

To be eligible for this award, candidates:

• Need not be a member of AABB.
• Must have authored original research contributing to body of knowledge, international reputation in transfusion medicine or related field.
• Must be able to attend the AABB Annual Meeting and present an educational lecture.
• Must have a completed nomination form submitted during the nomination period.

Selection

Recipient is selected by the Landsteiner-Alter Award review and selection team of leaders and experts, appointed by the AABB Awards Committee and AABB President. Final candidate approved by the AABB Board of Directors.

Recognized at: Landsteiner-Alter Award and Lectureship session at the AABB Annual Meeting.

Please send all inquiries about this award to awards@aabb.org.

2024 Recipient

Michael P. Busch, MD, PhD

Citation:

In recognition of his critical, field-advancing research throughout his extraordinary career. Among Dr. Busch’s many accomplishments, his work has been vital in improving our understanding of viral and serological markers, as well as the infectivity of blood transfusions. His research played a significant role in helping the field to further develop strategies to reduce the risk of transfusion-transmitted infections, thus improving the safety of blood transfusion and biotherapies worldwide.

View All Recipients